SBIR/STTR Research Award

Assessing toxicity with an ex vivo erythropoiesis system

Award identifier ea13b6ee2664c63723d52cf44584c1bc8d11a6e2c9f8ba8c61f227312e02d63fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Litron Laboratories Ltd
Proposal award date
Not reported
Contract end date
Not reported
UEI
LJH7LE9AUHL5
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Humans are exposed to toxic chemical and physical agents through a variety of sources. Of extreme concern are agents which can damage DNA, as genotoxicity is associated with cancer, atherosclerosis, and birth defects. The research effort proposed herein is aimed at developing murine ex vivo culture system that is capable of detecting agents which damage chromosomes through clastogenic and aneugenic activity. Currently, chemical-induced chromosome damage is evaluated by scoring chromosome abberations or micronucleus formation in cell lines or in laboratory rodents. By developing an ex vivo erythropoiesis system, reticulocytes can be generated in culture which serve as source material for micronucleus scoring. The primary cultures should provide more relevant toxicity information compared to immortilized cell lines. Furthermore, the feasibility of developing a flow cytometric scoring technique to enumerate micronuclei in ex vivo-derived reticulocytes is high, and overcomes artifacts associated with automated scoring of the standard in vitro assay. Relative to rodent tests, the proposed primary culture system will require few animals. To investigate the feasibility and utility of a genetic toxicity screening system based on ex vivo erythropoiesis, we will: 1. EVALUATE reticulocyte cell production by ex vivo culture(s). 2. MEASURE the frequency of micronuclei in ex vivo derived reticulocytes. 3. DETERMINE the responsiveness of the system to known clastogens and a model aneugen.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

42 SBIR/STTR records share this UEI (1985–2025). Reported award amounts total $18,400,554. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.